MRM Health Strengthens Board with Michel Detheux as Chairman and Hans-Jürgen Wörle as Independent Director as MH002 Advances Through Phase 2b

Contributed by: Business Wire

Logo

Tags

Research

Finance

Clinical Trials

Professional Services

Biotechnology

Health

Pharmaceutical

Science

Oncology

MRM Health

More Like This

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline

MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors

MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)

MRM Health Initiates Clinical Research in Parkinson’s Disease

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

Vertex Appoints Michel Lagarde to its Board of Directors

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis